Issue 83, 2020

Two-photon photodynamic ablation of tumour cells using an RGD peptide-conjugated ruthenium(ii) photosensitiser

Abstract

An RGD-peptide conjugated ruthenium(II) complex has been developed, which functions as a two-photon absorption (TPA) photodynamic therapy (PDT) agent for ablating tumours by selectively targeting the mitochondria of integrin αvβ3-rich tumour cells. This approach offers a new and effective design and application for tumour-targeting metallo-anticancer drugs via two-photon PDT.

Graphical abstract: Two-photon photodynamic ablation of tumour cells using an RGD peptide-conjugated ruthenium(ii) photosensitiser

Supplementary files

Article information

Article type
Communication
Submitted
19 Jul 2020
Accepted
08 Sep 2020
First published
09 Sep 2020

Chem. Commun., 2020,56, 12542-12545

Two-photon photodynamic ablation of tumour cells using an RGD peptide-conjugated ruthenium(II) photosensitiser

Z. Zhao, K. Qiu, J. Liu, X. Hao and J. Wang, Chem. Commun., 2020, 56, 12542 DOI: 10.1039/D0CC04943C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements